PrimeC

NeuroSense Reports Positive Phase 2b PrimeC ALS Results

Cambridge, Massachusetts, March 16, 2026 NeuroSense Therapeutics Ltd. announced the publication of results from its PARADIGM Phase 2b clinical...

By cGxPwire Editor
March 17, 2026

.Clinical Bio-Pharma

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...

By cGxPwire Editor
September 4, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

PrimeC

NeuroSense Reports Positive Phase 2b PrimeC ALS Results

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price